© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. BRAF and MEK inhibitors are not established treatments for non-V600 mutation-positive metastatic melanoma. We carried out a retrospective analysis of efficacy and safety in four patients with BRAF K601E and one patient with L597Q mutation-positive metastatic melanoma treated with the MEK inhibitor trametinib. Three patients achieved a RECIST partial response, including the patient with an L597Q mutation. Paired biopsies available in one of the five patients showed reduced phospho-ERK signalling and this corresponded to a metabolic response on 18F-fluorodeoxyglucose-PET scanning. Trametinib toxicity was manageable. Trametinib has antitumour activity in patients with BRAF K601E and L597Q mutation-positive metastatic melanoma.
Bowyer, S. E., Rao, A. D., Lyle, M., Sandhu, S., Long, G., Mcarthur, G. A., ... Millward, M. (2014). Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Research, 24(5), 504-508. https://doi.org/10.1097/CMR.0000000000000099